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The onset of brain lesions resulting from non-small-cell lung
cancer (NSCLC) is associated with a poor prognosis, with only
5% of patients surviving beyond the first year after diagnosis.1
Only a minority of carefully selected patients can be recom-
mended for surgical resection of brain metastases.2 Palliative
brain radiotherapy (BRT) could be efficacious in improving
symptoms and quality of life.3
However, growing evidence demonstrates that inappropri-
ate execution of the MET-driven “invasive growth” program is
implicated in the metastatic process and that MET overexpres-
sion promotes radiation-induced tumor invasiveness.4,5
Here, we assessed the METmolecular status in a relevant se-
ries of surgical samples from primary NSCLC, along with the
corresponding brain metastases, in order to decipher the role
of MET in predicting patients’ outcomes and radiotherapy
responsiveness.
A total of 68 NSCLC samples and their matched brainmetas-
tases were retrieved from consecutive cohorts from the
archives of the pathology divisions of the University of Turin
at the Citta` della Salute e della Scienza, Molinette Hospital of
Turin and of San Luigi Hospital, Orbassano, Italy. The study re-
ceived ethical approval from local institutional review boards.
Each sample was independently reviewed by 2 dedicated pathol-
ogists (R.S. and P.C.), who confirmed all diagnoses according to
the current World Health Organization classification.6 We ana-
lyzed the entire coding sequence ofMET, together with gene am-
plification by fluorescence in situ hybridization analysis, as already
described.7 Age, gender, and radiotherapy of primary tumor and
brain metastases, histotypes, and survival were ascertained for
each case. Descriptive statistics were produced for demographic,
clinical, and laboratory characteristics of cases. Cox regression
was used to determine the association of patients’ characteristics
with survival following diagnosis of brain metastases.
The cohort analyzed was characterized as follows. Of the 68
cases, 15 were female (22%) and 53 were male (78%); the
mean age at diagnosis was 63.2+9.1 years; the cumulative
follow-up was 1438 patient-months, with amedian overall sur-
vival of 12 months (interquartile range, 7–39). The adenocarci-
noma histotype was represented in 54.4% of cases (37
patients); squamous cell carcinoma was detected in 20.5% of
cases (14 patients), whereas neuroendocrine lineage occurred
in 10.2% of cases (7 patients). The remaining 10 patients dis-
played undifferentiated carcinomas. All the studied patients
underwent surgical removal of both the primary mass and
the brain metastasis. Brain surgery followed the removal of
the primary mass (from 1 to 15 mo); in one case the brain le-
sion was diagnosed and removed 1 month before the appear-
ance of the primary lung tumor. Of all the patients, 73.5% (50
patients) underwent BRT after surgery.
In line with reported data (COSMIC database, http://cancer.
sanger.ac.uk/cosmic), somatic MET mutations occurred in
4.41% (3) of primary lung tumors; 19.12% of those samples
(13) harbored an increased MET gene copy number. We then
investigated the MET molecular profile of metastatic brain
lesions. Unexpectedly, 7.35% of patients (5) displayed activating
MET mutations, while 22.39% of lesions (15 patients) were MET
amplified. Two cases harbored mutations in both the primary
and themetastatic lesion. Coexistence ofMETmutation and am-
plificationwas not detected in any of the analyzed cases. Related
clinical and molecular data are shown in detail in Table 1.
Notably, themortality rate after BRTwas significantly higher in
tumors carrying MET somatic mutations compared with euploid
MET wild-type lesions (hazard ratio, 4.39; 95% CI, 1.46–13.18;
P, .008).
Overall, our findings have documented that the occurrence
of MET mutations in brain metastasis from NSCLC neutralized
the favorable effect of BRT, thus predicting a worse patients’
outcome. Although preliminary, our findings are coherent
with published data suggesting that MET targeting may impair
radioresistance.8 Moreover, for the first time, our results
strongly indicate that MET activation by somatic mutations is
associated with substantial radioresistance of highly invasive
NSCLC. The above described MET mutations have 2 clinical im-
plications: (i) a potential functional marker of highly aggressive
lung tumors, easily detectable in the near future by the “liquid
biopsy” approach9; (ii) a rationale for clinical trials with MET in-
hibitors in patients carrying advanced brain metastatic disease,
directed to radiotherapy.
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Table 1. Clinico-pathological and molecular profile of the MET-mutated brain metastases
Pt 1 Pt 2 Pt 3 Pt 4 Pt 5
Gender M M F F F
Age at diagnosis (y) 56 80 59 43 69
Histotype U LCNE ADC ADC ADC
Brain metastatic site Parietal lobe (r) Frontal lobe Parietal lobe (r) Sella Cerebellum
Number of brain lesions 1 1 1 1 1
MET mutational status
Lung T1010I Wt Wt Wt Wt
Brain T1010I E168D E168D E168D T1010I
MET copy number
Lung 2 2 2 2 2
Brain 2 2 2 2 2
EGFR exon 18–21 Wt Wt Wt Wt Wt
KRas exon 2 Wt Wt Wt Wt Wt
Overall survival (mo) 7 2 9 40 7
TtP (mo) 5 0 1 39 2
Survival from metastasis (mo) 2 2 1 1 4
Radiotherapy
Lung No No Yes No No
Brain Yes Yes Yes Yes Yes
Type of radiotherapy Stereotactic Stereotactic Stereotactic Stereotactic Stereotactic
Abbreviations: U, undifferentiated carcinoma; ADC, adenocarcinoma; LCNE, large-cell neuroendocrine carcinoma; TtP, time to progression; EGFR,
epidermal growth factor receptor; Wt, wild type; KRas, Kirsten rat sarcoma viral oncogene homolog.
All the MET mutations were found clustered either in the juxtamembrane or in the extracellular semaphorin domain of the receptor. Both the
T1010I and the E168D changes are already established somatic mutations, previously reported in both non-small- and small-cell lung cancers,
displaying documented tumorigenic potential. None of theMET-mutated patients underwent chemotherapy after surgical removal of both prima-
ry and secondary lesions.
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